11/07/2013 18:45:00

U.K. Recalls Drugs Made in India

LONDON--In another sign of possible manufacturing problems in India's pharmaceutical industry, the U.K.'s medicines regulator said it was recalling 16 drugs made by Wockhardt Ltd. (532300.BY) after finding "manufacturing deficiencies" at one of the company's factories in India.

The Medicines and Healthcare products Regulatory Agency, or MHRA, called it a "precautionary recall," as there is no evidence that the medicines are defective. The agency said it is recalling the drugs from pharmacies and wholesalers but isn't asking patients to return their Wockhardt medicines.

"There is no evidence of a patient safety risk. ...however, the MHRA has to act in the interest of public health as poor manufacturing standards cannot be allowed to continue," the agency said.

The recalled drugs, manufactured in the central Indian city of Waluj, include treatments for infections, hypertension, diabetes, epilepsy and other diseases. The MHRA said the plant suffered from "poor cleaning practices" and defective ventilation systems. The agency inspection also found evidence of "forged documents relating to staff training records."

In an emailed statement, Wockhardt confirmed the news and said the recall would result in a one-time charge of 1.5 million pounds ($2.25 million) this year. Exports from the Waluj plant constitute less than 5% of the company's total U.K. sales and less than 2% of overall sales, it added.

It was the second recent setback for the company and its Waluj factory. In May, the U.S. Food and Drug Administration imposed an import ban on products from the factory after it failed an FDA safety inspection. The FDA didn't elaborate on the problems it found.

In a conference call at the time, Wockhardt Chairman Habil Khorakiwala said the company was implementing "corrective measures to be in compliance with the FDA guidelines." He said the U.S. import ban could cost the company $100 million in revenue this fiscal year. Wockhardt generated total revenue of 25.6 billion rupees ($460.6 million) in the year ended March 31, 2012.

Also in May, India's Ranbaxy Laboratories Ltd. (500359.BY) agreed to pay $500 million in civil and criminal fines for exporting adulterated drugs to the U.S.

In a phone interview Thursday, D.G. Shah, secretary-general of the Indian Pharmaceutical Alliance, an industry body, said the group has written to the FDA asking it to conduct workshops with Indian companies to correct erroneous practices.

"Companies need to better understand FDA processes, and there needs to be a correction in their organizational culture, right from drug discovery to development and production," Mr. Shah said.

Write to Jeanne Whalen at jeanne.whalen@wsj.com and Anirban Chowdhury at anirban.chowdhury@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

July 11, 2013 13:45 ET (17:45 GMT)

Copyright (c) 2013 Dow Jones & Company, Inc.

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
23 May
ZEAL
Zealand Pharma havde i sammenhæng med deres Q1 resultat et web-cast, hvor ledelsen kommenterede på s..
31
27 May
 
DET BETYDER ALT (LÆS SIDSTE 10-11 LINJER FØRST, DET ER DET JEG HAR LEVET EFTER - OG DET HAR FANDEME ..
23
21 May
 
”Verdensøkonomiens nuværende vigtigste sektor må være Kinas boligmarked. Der står 50 mio. lejlighede..
21
25 May
VELO
Efter aflæggelse af Q1 2015 afholdt Veloxis en telefonkonference om resultatet og                 fo..
20
22 May
VWS
BHE Renewables LLC, der er ejet af Warren Buffett's Berkshire Hathaway Energy og som for nyligt best..
15
27 May
BIOPOR
  Tillykke til alle dem der har tjent godt på Bioporto de sidste par uger og specielt de sidste par ..
14
24 May
VWS
Hvis man ikke mere vil bruge dette forum, skal man så bede EI om at slette en???? Tænk, jeg troede m..
14
23 May
VWS
Giver dig ret i at MENA er dygtig, men hans sprogbrug gør bare at man ikke gider læse hvad han skriv..
10
23 May
 
Hermed status på portefølje nr.6 i millionærklubben. For årets udbytter har jeg købt Johnson og john..
10
26 May
 
Jeg er meget enig med dig i praktisk taget hvert et ord, som du skriver. Hvis jeg skal tilføje noget..
9

Form 8.3 - Synergy Health Plc

27/05/2015 15:25:23
  FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESEN..

Alliance Trust PLC : Net Asset Value(s)

27/05/2015 12:47:21
ALLIANCE TRUST PLC At the close of business on Tuesday 26 May 2015, the unaudited net asset value per ordinary share of 2.5p, valued on a bid price bas..

Total voting rights

27/05/2015 10:58:31
27th May 2015 Intermediate Capital Group plc TOTAL VOTING RIGHTS Intermediate Capital Group plc (the "Company") has made an application for the admi..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
THE EUROPEAN INVESTMENT TRUST PLC - Half-yearly Report
2
Höegh LNG - Awarded FSRU Contract in Chile
3
VALOE CORPORATION, INTERIM REPORT FOR JANUARY - MARCH 2015
4
Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA
5
OCEANTEAM SHIPPING ASA - RELEASE OF Q1 2015 REPORT AND PRESENTATION

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2015   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
28 May 2015 00:47:16
(UTC) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20150519.1 - EUROWEB7 - 2015-05-28 01:47:16 - 2015-05-28 00:47:16 - 1000 - Website: OKAY